Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yabao Gains China Rights to Stroke Treatment from Primary Peptides

publication date: Sep 16, 2015
Yabao Pharma added another project to its development portfolio of innovative drugs by in-licensing greater China rights to a candidate for stroke treatment from Primary Peptides of Vancouver. Primary Peptides, which develops peptides that inhibit protein-protein interaction, says the K13 peptide was effective in animal models, even if administered as long as six hours after stroke onset. Yabao is busy on the deal-making front. One week ago, it announced a collaboration with the University of South Australia to develop new cancer drugs. More details....

Stock Symbol: (SHA: 600351)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital